Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF54ZG)

Drug Name
Sulpiride Drug Info
Synonyms
Abilit; Aiglonyl; Alimoral; Arminol; Calmoflorine; Championyl; Coolspan; Darleton; Deponerton; Desisulpid; Desmenat; Digton; Dobren; Dogmatil; Dogmatyl; Dolmatil; Dresent; Eglonil; Eglonyl; Ekilid; Enimon; Equilid; Eusulpid; Fardalan; Fidelan; Guastil; Isnamide; Kylistro; Lebopride; Levobren; Levopraid; Levosulpirida; Levosulpiridum; Lisopiride; Mariastel; Meresa; Miradol; Mirbanil; Misulvan; Neogama; Norestran; Normum; Nufarol; Omiryl; Omperan; Ozoderpin; Pontiride; Psicocen; Pyrikappl; Pyrkappl; Restful; Sernevin; Splotin; Stamonevrol; Sulp; Sulperide; Sulpirid; Sulpirida; Sulpiridum; Sulpitil; Sulpivert; Sulpor; Sulpride; Sulpyrid; Suprium; Sursumid; Synedil; Tepavil; Valirem; Zemorcon; Allphar Brand of Sulpiride; Almirall Brand of Sulpiride; Areu Brand of Sulpiride; Centrum Brand of Sulpiride; Desitin Brand of Sulpiride; Dolorgiet Brand of Sulpiride; Erempharma Brand of Sulpiride; Fumouzer Brand of Sulpiride; Hennig Brand of Sulpiride; Hexal Brand of Sulpiride; Hoechst Brand of Sulpiride; Hormosan Brand of Sulpiride; Krewel Brand of Sulpiride; Levosulpiride [INN]; Magnetic resonance imaging sulpiride; Pharmacia Brand of Sulpiride; Psicofarma Brand of Sulpiride; Rosemont Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Spyfarma Brand of Sulpiride; Uriach Brand of Sulpiride; Vertigo Meresa; Vertigo neogama; RD 1403; S 8010; Bosnyl (TN); Dogmatil (TN); Dogmatyl (TN); Eglonyl (TN); Levosulpirida [INN-Spanish]; Levosulpiridum [INN-Latin]; Meresa (TN); Neuraxpharm (TN); RV-12309; Ratiopharm (TN); Sanofi-Synthelabo Brand of Sulpiride; Sulpirid (TN); Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpiryd (TN); Vertigo-Meresa; Vertigo-neogama; R. D. 1403; R.D. 1403; Sulpiride (JP15/USAN/INN); Sulpiride [USAN:INN:BAN:JAN]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (+/-)-Sulpiride; (RS)-(+/-)-sulpiride; (inverted question mark)-Sulpiride
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Antipsychotic Agents
Cross-matching ID
PubChem CID
5355
ChEBI ID
CHEBI:32168
CAS Number
CAS 15676-16-1
TTD Drug ID
DMF54ZG
VARIDT Drug ID
DR01168

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [8]
Haloperidol DM96SE0 Delirium Approved [9]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [10]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [11]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [12]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [13]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [14]
Pimozide DMW83TP Schizophrenia 6A20 Approved [15]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [16]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 1 (SLC15A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [18]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [19]
Ampicillin DMHWE7P Acute epiglottitis Approved [20]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [21]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [22]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [23]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [24]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [19]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [21]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(2) dopamine receptor (DRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Droperidol DM0DXA8 Nausea MD90 Approved [25]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [25]
Zuclopenthixol DMKYD5N Schizophrenia 6A20 Approved [25]
Meglitinides DM1OFHN Type-2 diabetes 5A11 Approved [26]
Risperidone DMN6DXL Bipolar I disorder Approved [27]
Olanzapine DMPFN6Y Bipolar depression Approved [28]
Methamphetamine DMPM4SK Anxiety Approved [29]
Bromocriptine DMVE3TK Acromegaly 5A60.0 Approved [30]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [31]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prolactin (PRL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [33]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [34]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [35]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [36]
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [38]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [39]
Aripiprazole DM3NUMH Bipolar I disorder Approved [40]
Fluoxetine DM3PD2C Bipolar depression Approved [41]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Insulin (INS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Epinephrine DM3KJBC Acute asthma CA23 Approved [44]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [45]
Fructose DM43AN2 Vomiting MD90 Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [47]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [48]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [49]
Propranolol DM79NTF Angina pectoris BA40 Approved [50]
Testosterone DM7HUNW Hot flushes GA30 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [52]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [53]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [54]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [55]
Cepharanthine DM9Y5JB N. A. N. A. Approved [56]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [57]
Clozapine DMFC71L Schizophrenia 6A20 Approved [58]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [59]
Trifluoperazine DMKBYWI Anxiety Approved [60]
Olanzapine DMPFN6Y Bipolar depression Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [61]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [61]
Norepinephrine DMOUC09 Alopecia ED70 Approved [61]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [63]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [64]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [65]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [67]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [69]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [69]
Gefitinib DM15F0X Colon adenocarcinoma Approved [70]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [25]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [71]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [72]
Methotrexate DM2TEOL Anterior urethra cancer Approved [73]
Quercetin DM3NC4M Obesity 5B81 Approved [74]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [75]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [76]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [4]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Regulation of Drug Effects [4]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Protein Interaction/Cellular Processes [5]
Insulin (INS) OTZ85PDU INS_HUMAN Gene/Protein Processing [6]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Gene/Protein Processing [7]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Regulation of Drug Effects [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 960).
2 The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
3 Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Oct;25(10):1345-50.
4 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
5 Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
6 Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006 Jul;186(4):572-8. doi: 10.1007/s00213-006-0384-5. Epub 2006 Apr 7.
7 D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men. J Clin Endocrinol Metab. 1987 Aug;65(2):368-9. doi: 10.1210/jcem-65-2-368.
8 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
9 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
10 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
11 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
12 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
14 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
15 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
16 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
17 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
19 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
20 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
21 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
22 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
23 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
24 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
25 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
26 Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
27 Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
28 Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
29 A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
30 Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
31 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
32 Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. doi: 10.1016/j.neulet.2004.11.014. Epub 2004 Dec 2.
33 Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
34 [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
35 Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
36 Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
37 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
38 The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
39 Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
40 The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
41 Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
42 Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
43 Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
44 A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
45 Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
46 Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
47 Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
48 Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
49 Clonidine effect on insulin secretion and lipolysis in man. Acta Diabetol Lat. 1978 May-Aug;15(3-4):192-7. doi: 10.1007/BF02581064.
50 Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
51 Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
52 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
53 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
54 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
55 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
56 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
57 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
58 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
59 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
60 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
61 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
62 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
63 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
64 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
65 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
66 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
67 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
68 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
69 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
70 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
71 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
72 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
73 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
74 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
75 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
76 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.